Halozyme Therapeutics, Inc. Shares Outstanding 2009–2025
Halozyme Therapeutics, Inc. reported 117.8M of shares outstanding for fiscal 2025. That was 4.3% lower than fiscal 2024. Compared with fiscal 2020, the change was -12.8%. A falling share count is consistent with net buybacks exceeding issuance over the period, though the filing should be checked for the components.
| Fiscal year | Shares Outstanding | Change (YoY) |
|---|---|---|
| FY 2025 | 117.8M | -4.3% |
| FY 2024 | 123.1M | -2.9% |
| FY 2023 | 126.8M | -6.2% |
| FY 2022 | 135.2M | -1.7% |
| FY 2021 | 137.5M | +1.8% |
| FY 2020 | 135.0M | -1.2% |
| FY 2019 | 136.7M | -5.5% |
| FY 2018 | 144.7M | +1.4% |
| FY 2017 | 142.8M | +10.3% |
| FY 2016 | 129.5M | +1.1% |
| FY 2015 | 128.2M | +1.9% |
| FY 2014 | 125.7M | +9.8% |
| FY 2013 | 114.5M | +1.6% |
| FY 2012 | 112.7M | +8.4% |
| FY 2011 | 104.0M | +3.4% |
| FY 2010 | 100.6M | — |
| FY 2009 | 0.0M | — |
Source: Halozyme Therapeutics, Inc. SEC filings — balance sheet (10-K), split-adjusted. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open HALO 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Halozyme Therapeutics, Inc. reported 117.8M of shares outstanding for fiscal 2025. That was 4.3% lower than fiscal 2024. Compared with fiscal 2020, the change was -12.8%. A falling share count is consistent with net buybacks exceeding issuance over the period, though the filing should be checked for the components. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Halozyme Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHalozyme Therapeutics, Inc. — frequently asked questions
What is Halozyme Therapeutics, Inc.'s shares outstanding?
Halozyme Therapeutics, Inc. (HALO) reported shares outstanding of 117.8M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Halozyme Therapeutics, Inc.'s official SEC filings (balance sheet (10-K), split-adjusted), refreshed nightly. Not investment advice.
More HALO financial history
Full HALO fundamentals page → · Analyze shares outstanding with a free tool → · Research guide & leaders → · All 1,500+ companies →